Twist Bioscience Reports Second Quarter Fiscal 2019 Financial Results and Highlights Commercial and Operational Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Twist Bioscience Corporation (TWST) Tops Q2 EPS by 4c, Revenues Beat; FY19 Revenue Guidance Above Consensus
April 30, 2019 5:07 PM EDTTwist Bioscience Corporation (NASDAQ: TWST) reported Q2 EPS of ($0.93), $0.04 better than the analyst estimate of ($0.97). Revenue for the quarter came in at $13.56 million versus the consensus estimate of $12.02 million.
We continue to post strong topline growth as we extend our reach and diversify our revenue stream from our synbio customers, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist. For NGS, we continue to expand our base of customers rapidly, adding several in production and a larger number in pilot. Importantly, we... More
